776 results on '"Avsar M"'
Search Results
2. Ten-Year Experience with Peritransplant Desensitization in Patients with Preformed Donor Specific Antibodies in Lung Transplantation
3. Waitlist Stratification and Outcomes in Lung Transplantation for Severe Pulmonary Hypertension
4. Ten-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation
5. Association of Higher CD4+CD25highCD127low, FoxP3+, and IL-2+ T Cell Frequencies Early After Lung Transplantation With Less Chronic Lung Allograft Dysfunction at Two Years
6. Lung Transplantation in Patients with Severe Pulmonary Hypertension: a 13-Year Single-Center Experience.
7. In Vivo Development of Transplant Arteriosclerosis in Humanized Mice Reflects Alloantigen Recognition and Peripheral Treg Phenotype of Lung Transplant Recipients
8. Phenotyping Chronic Lung Allograft Dysfunction Using Body Plethysmography and Computed Tomography
9. (908) Does Donor-Recipient Sex Mismatch Have an Influence on Long Term Outcomes after Lung Transplantation? An Experience of a High Volume Center
10. (1264) Recipients of Extended Criteria Ex Situ Preserved Lungs Display Higher Plasma Levels of Cytokines and Endothelial Markers after Lung Transplantation Without Higher PGD Scores
11. (410) Perioperative Desensitization Changes the Plasma Cytokine Milieu in Lung Transplant Patients with Preformed Donor Specific Antibodies
12. 12-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Arterial Hypertension
13. (101) Nine-Year Experience with Treatment of Early Detectable Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients
14. (120) Heart Preservation with the Organ Care System in Extended Criteria Donor Hearts: A Single Center Experience
15. Augmentation of Transient Donor Cell Chimerism and Alloantigen-Specific Regulation of Lung Transplants in Miniature Swine
16. Is Repeated Pulmonary Valve Replacement a Safe and Effective Procedure?
17. Nine-Year Experience with Perioperative Desensitization in Patients with Preformed Donor-Specific Antibodies in Lung Transplantation
18. Nine-Year Experience with Treatment of Early Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients
19. Bilateral Lung Transplantation for Pediatric Pulmonary Arterial Hypertension: Perioperative Management and One-Year Follow-up
20. Kunstherz als Langzeittherapie älterer Patienten mit terminaler Herzinsuffizienz
21. Eight-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation
22. Primary Graft Dysfunction Following Lung Transplantation is Associated with Increased In Vivo T Cell Alloreactivity: Evidence from a Humanized Mouse Model
23. Using Donor Lungs ≥70 Years of Age for Transplantation - Do Long-Term Outcomes Justify the Use?
24. Perioperative Desensitization with IgA- and IgM-Enriched Human Immunoglobulins Allows Safe Lung Transplantation in Patients with Preformed Donor Specific Antibodies
25. Liver-First Strategy for Combined Lung and Liver Transplantation: 15-Year Single-Center Experience
26. Lung Transplantation and Concomitant Coronary Artery Bypass Grafting Does Not Impair Patient Outcomes: Insights from a Single-Center Experience
27. (908) - Eighteen-Year Single Center Experience with Lung Transplantation in Pediatric Patients Younger Than 12 Years Old
28. (1276) - Combined Heart and Lung Transplantation Across Preformed Donor-Specific Antibodies Using a Peritransplant Desensitization Protocol
29. (699) - Ten-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation
30. (698) - Ten-Year Experience with Peritransplant Desensitization in Patients with Preformed Donor Specific Antibodies in Lung Transplantation
31. (16) - Waitlist Stratification and Outcomes in Lung Transplantation for Severe Pulmonary Hypertension
32. Eight-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Possible Subclinical and Clinical Antibody-Mediated Rejection after Lung Transplantation
33. Preformed Donor-Specific Antibodies in Lung Transplantation: Eight-Year Experience with Perioperative Desensitization Using IgA- and IgM-Enriched Human Immunoglobulins
34. Fontan Fenestration: Postoperative Hemodynamic Relief or Additional Trauma and Cyanosis?
35. Primary Graft Dysfunction following Lung Transplantation Is Associated with Increased In Vivo T-Cell Alloreactivity
36. Impact of Donor Quality on Recipient Outcomes in Lung Transplantation: 11-Year Single-Center Experience Using the Eurotransplant Lung Donor Score
37. Lifetime Endocarditis Risk with Congenital Heart Disease and Pulmonary Valve Prosthesis (PVP): Results from the German Registry for Congenital Heart Defects (CHD)
38. MODULATION OF IMMUNE-MEDIATORS FROM DONOR LUNGS USING THE ORGAN CARE SYSTEM® - A POTENTIAL MECHANISM FOR IMPROVED OUTCOME: V06
39. Donor Oxygenation Has No Impact On Postoperative Outcome After Lung Transplantation.: Abstract# C2008
40. Treatment With Donor Specific Alloantigen 28 Days Before or On the Day of Lung Transplantation- A Comparison in a Large Animal Model.: Abstract# D2754
41. Modulation of Immune-Mediators From Donor Lungs Using the Organ Care System®- A Potential Mechanism for Improved Outcome.: Abstract# C2076
42. Differential Outcomes for Long Term Ex Vivo Lung Perfusion in a Porcine Model -With or Without Red Cells?: Abstract# C1643
43. In a Fully Allogeneic Mouse Aorta Transplantation Model Physical Exercise Reduces Transplant Arteriosclerosis.: Abstract# A111
44. Developing a Score of Early Postoperative Regulatory T Cell Frequency to Predict Bronchiolitis Obliterans Syndrome-Free Survival at Two Years After Lung Transplantation.: Abstract# 1385
45. Extending Donor Criteria in Lung Transplantation- Donors 70 Years and Older.: Abstract# 2101
46. Seven-Year Clinical Results of an IgA-and IgM-Enriched Human Immunoglobulin-Based Therapy for Antibody-Mediated Rejection after Lung Transplantation
47. Heart-Associated Cytokine and Endothelial Patterns Dominate the Ischemia/Reperfusion Response in Recipients of Combined Heart/Lung Transplantation in Comparison to Lung Transplantation
48. Treatment of Anti-HLA Donor-Specific Antibodies in Heart Transplantation: A Single-Center Experience
49. Ex Situ Heart Perfusion and Standard of Care Cold Storage Differentially Affect the Ischemic Secretome of Donor Hearts in Perfusates but Not the Reperfusion Response in Recipient Plasma
50. Fifteen-Year Single Center Experience with Lung Transplantation in Pediatric Patients Younger Than 12 Years Old
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.